FLEX NATION

[BioSpecialist]

ACRS..Trading HEAVILY under Cash and with lotsof upcoming news :

ACRS = Market Cap $43 M / Cash $115 M or untill end 2021 / 2 Marketed Products / 1 Phase 3 trial (common warts) with results expected in Q4 2019 and many other phase 2 programs / because of their strategic change they wants to out-license all their Prodcuts which means HUGE upfront payments for the company in short term (more infos below)= CHEAPEST Biotech you can get at this time could triple very quickly



Aclaris Therapeutics (ACRS)

Market Cap: $43 M
Cash: $115 M or enough untill end 2021
Price 1.08


Aclaris Therapeutics Announces New Strategic Direction
https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-new-strategic-direction


ACRS aquired a attractive drug from Allergan last year paid $65 m upfront alone for this drug which they now looking to outlicense .
https://www.globenewswire.com/news-release/2018/10/15/1621519/0/en/Aclaris-Therapeutics-to-Acquire-Worldwide-Rights-to-RHOFADE-from-Allergan.html


Pipeline
https://www.aclaristx.com/pipeline/


Largest Shareholders:

Deerfield Management Company LP...5 893 416
Franklin Advisers, Inc....3 953 203
BlackRock Fund Advisors ...2 359 223
Broadfin Capital LLC...2 280 260
D. E. Shaw & Co. LP....2 049 462
Sofinnova Ventures, Inc.....1 911 573
Vivo Capital LLC ....1 647 214
Fidelity Management & Research Co...1 562 190
Polar Capital LLP...1 443 920
The Vanguard Group, Inc...1 142 022